Redcare Pharmacy（1RDC）株式概要Redcare Pharmacy NVはオランダ、ドイツ、イタリア、ベルギー、スイス、オーストリア、フランスでオンライン薬局事業を展開している。 詳細1RDC ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より81.5%で取引されている 収益は年間58.64%増加すると予測されています リスク分析過去3か月間に大規模なインサイダー売却が発生 Italian市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る1RDC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW460,134 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA460,134 investors already sharing narrativesYour Fair Value€Current Price€62.0525.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-105m5b2016201920222025202620282031Revenue €5.3bEarnings €159.1mAdvancedSet Fair ValueView all narrativesRedcare Pharmacy NV 競合他社PiùMedicalSymbol: BIT:PMEDMarket cap: €43.7mMARRSymbol: BIT:MARRMarket cap: €397.0mOrseroSymbol: BIT:ORSMarket cap: €268.9mAin HoldingsSymbol: TSE:9627Market cap: JP¥212.3b価格と性能株価の高値、安値、推移の概要Redcare Pharmacy過去の株価現在の株価€62.0552週高値€91.9552週安値€35.44ベータ1.421ヶ月の変化-7.46%3ヶ月変化31.46%1年変化-33.78%3年間の変化-41.05%5年間の変化-58.47%IPOからの変化62.43%最新ニュースReported Earnings • Jul 30Second quarter 2026 earnings released: EPS: €0.23 (vs €0.46 in 2Q 2025)Second quarter 2026 results: EPS: €0.23 (down from €0.46 in 2Q 2025). Revenue: €853.5m (up 20% from 2Q 2025). Net income: €4.70m (down 50% from 2Q 2025). Profit margin: 0.6% (down from 1.3% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 16% per year.Breakeven Date Change • Jul 29The 9 analysts covering Redcare Pharmacy previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 73% to 2026. The company is expected to make a profit of €17.9m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.お知らせ • Jul 29Redcare Pharmacy NV to Report Fiscal Year 2026 Results on Mar 04, 2027Redcare Pharmacy NV announced that they will report fiscal year 2026 results on Mar 04, 2027Recent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.お知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.最新情報をもっと見るRecent updatesReported Earnings • Jul 30Second quarter 2026 earnings released: EPS: €0.23 (vs €0.46 in 2Q 2025)Second quarter 2026 results: EPS: €0.23 (down from €0.46 in 2Q 2025). Revenue: €853.5m (up 20% from 2Q 2025). Net income: €4.70m (down 50% from 2Q 2025). Profit margin: 0.6% (down from 1.3% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 16% per year.Breakeven Date Change • Jul 29The 9 analysts covering Redcare Pharmacy previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 73% to 2026. The company is expected to make a profit of €17.9m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.お知らせ • Jul 29Redcare Pharmacy NV to Report Fiscal Year 2026 Results on Mar 04, 2027Redcare Pharmacy NV announced that they will report fiscal year 2026 results on Mar 04, 2027Recent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.お知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.お知らせ • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026お知らせ • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.お知らせ • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026お知らせ • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.Reported Earnings • Oct 30Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €719.2m (up 25% from 3Q 2024). Net loss: €7.24m (loss widened 4.8% from 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Europe.New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Significant insider selling over the past 3 months (€307k sold).お知らせ • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.Reported Earnings • Jul 29Second quarter 2025 earnings released: EPS: €0.46 (vs €0.21 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.46 (up from €0.21 loss in 2Q 2024). Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up €13.6m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025お知らせ • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.株主還元1RDCIT Consumer RetailingIT 市場7D0.3%-1.7%-1.6%1Y-33.8%-2.3%19.0%株主還元を見る業界別リターン: 1RDC過去 1 年間で-2.3 % の収益を上げたItalian Consumer Retailing業界を下回りました。リターン対市場: 1RDCは、過去 1 年間で19 % のリターンを上げたItalian市場を下回りました。価格変動Is 1RDC's price volatile compared to industry and market?1RDC volatility1RDC Average Weekly Movement7.6%Consumer Retailing Industry Average Movement4.1%Market Average Movement4.2%10% most volatile stocks in IT Market7.9%10% least volatile stocks in IT Market2.7%安定した株価: 1RDCの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1RDCの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20012,163Olaf Heinrichwww.redcare-pharmacy.comRedcare Pharmacy NVはオランダ、ドイツ、イタリア、ベルギー、スイス、オーストリア、フランスでオンライン薬局事業を展開している。処方箋医薬品と非処方箋の一般用医薬品、美容・パーソナルケア製品、食品サプリメントを提供している。以前はShop Apotheke Europe N.V.として知られ、2023年6月にRedcare Pharmacy NVに社名変更した。Redcare Pharmacy NVは2001年に設立され、オランダのセブナムに本社を置いている。もっと見るRedcare Pharmacy NV 基礎のまとめRedcare Pharmacy の収益と売上を時価総額と比較するとどうか。1RDC 基礎統計学時価総額€1.28b収益（TTM）-€42.00m売上高(TTM)€3.22b0.4xP/Sレシオ-30.4xPER（株価収益率1RDC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1RDC 損益計算書（TTM）収益€3.22b売上原価€2.52b売上総利益€693.70mその他の費用€735.70m収益-€42.00m直近の収益報告Jun 30, 2026次回決算日Oct 29, 2026一株当たり利益（EPS）-2.04グロス・マージン21.56%純利益率-1.31%有利子負債／自己資本比率74.7%1RDC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/19 06:27終値2026/08/19 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Redcare Pharmacy NV 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25 アナリスト機関Gerhard SchwarzBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchSarah RobertsBarclays22 その他のアナリストを表示
Reported Earnings • Jul 30Second quarter 2026 earnings released: EPS: €0.23 (vs €0.46 in 2Q 2025)Second quarter 2026 results: EPS: €0.23 (down from €0.46 in 2Q 2025). Revenue: €853.5m (up 20% from 2Q 2025). Net income: €4.70m (down 50% from 2Q 2025). Profit margin: 0.6% (down from 1.3% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 16% per year.
Breakeven Date Change • Jul 29The 9 analysts covering Redcare Pharmacy previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 73% to 2026. The company is expected to make a profit of €17.9m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
お知らせ • Jul 29Redcare Pharmacy NV to Report Fiscal Year 2026 Results on Mar 04, 2027Redcare Pharmacy NV announced that they will report fiscal year 2026 results on Mar 04, 2027
Recent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
お知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Reported Earnings • Jul 30Second quarter 2026 earnings released: EPS: €0.23 (vs €0.46 in 2Q 2025)Second quarter 2026 results: EPS: €0.23 (down from €0.46 in 2Q 2025). Revenue: €853.5m (up 20% from 2Q 2025). Net income: €4.70m (down 50% from 2Q 2025). Profit margin: 0.6% (down from 1.3% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 16% per year.
Breakeven Date Change • Jul 29The 9 analysts covering Redcare Pharmacy previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 73% to 2026. The company is expected to make a profit of €17.9m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
お知らせ • Jul 29Redcare Pharmacy NV to Report Fiscal Year 2026 Results on Mar 04, 2027Redcare Pharmacy NV announced that they will report fiscal year 2026 results on Mar 04, 2027
Recent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
お知らせ • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
お知らせ • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026
お知らせ • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.
お知らせ • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026
お知らせ • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.
Reported Earnings • Oct 30Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €719.2m (up 25% from 3Q 2024). Net loss: €7.24m (loss widened 4.8% from 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Europe.
New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Significant insider selling over the past 3 months (€307k sold).
お知らせ • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.
Reported Earnings • Jul 29Second quarter 2025 earnings released: EPS: €0.46 (vs €0.21 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.46 (up from €0.21 loss in 2Q 2024). Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up €13.6m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025
お知らせ • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.
